[Influence of combined, hypolipemic therapy on lipids and non-lipid atherosclerosis risk factors].
It is very difficult to reach therapeutic goals of lipids concentrations n patients with very high and high risk development of coronary heart disease during statin monotherapy. Treatment with high doses of statins is associated with significantly increase of serious adverse events, especially rhabdomiolysis. Therefore are taken much more often trials of the combined hypolipemic therapy. In this article, we briefly review the clinical trial data on the efficacy, safety and influence on non-lipid atherosclerosis factors of combined therapy statin with fibrates, statin with nicotinic acid and statin with ezetimibe.